Roche intends to complete Spark acquisition today Basel, 17 December 2019 – Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche’s wholly owned subsidiary 022019 Merger Subsidiary, Inc. has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all... Read more
All antitrust approvals required to close the transaction received. Basel, 16 December 2019 – Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that the Federal Trade Commission closed its investigation and granted unconditional clearance and termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976... Read more
Basel, 16 December 2019 – Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that the UK Competition and Markets Authority has unconditionally cleared Roche’s pending acquisition of Spark pursuant to its previously announced tender offer to purchase all of the outstanding shares of common stock (the “Shares”) of... Read more
Basel, 09 December 2019 Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. to December 16, 2019 Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has extended the offering period of its previously announced tender offer to purchase all... Read more
Fujifilm Establishes the Bio Science & Engineering Laboratories U.S.A. to Start Full-scale Translational Research for Biotherapeutics in the United States – Fujifilm Cellular Dynamics Usage of Cookies: Cookies are important to the proper functioning of this site. To improve your experience, we use cookies to remember log-in details and provide secure log-in, collect statistics to... Read more
Agilent Companion Diagnostic Expands CE-IVD mark in Europe to include Head and Neck Squamous Cell Carcinoma (HNSCC) PD-L1 IHC 22C3 pharmDx can now be used as an aid in identifying HNSCC patients for treatment with KEYTRUDA® (pembrolizumab) in Europe SANTA CLARA, Calif., November 22, 2019 Agilent Technologies, Inc. (NYSE: A) today announced that its PD-L1... Read more
Basel, 22 November 2019 Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has extended the offering period of its previously announced tender offer to purchase all of the outstanding shares... Read more
Agilent Announces New ICP-OES Systems with Innovative Instrument Intelligence Smart capabilities deliver deep insight into samples, processes, and operational status SANTA CLARA, Calif., November 19, 2019 Agilent Technologies, Inc. (NYSE: A) today announced a new generation of ICP-OES systems for laboratories serving the environmental, food, energy, chemicals, and materials markets. The new Agilent 5800 ICP-OES... Read more
Spectrum Two™ FT-IR spectrometer and software part of scientific collaboration with eXXpedition WALTHAM, Mass. – November 14, 2019 – PerkinElmer, Inc., a global leader committed to innovating for a healthier world, announced its Spectrum Two™ FT-IR spectrometer solution is onboard a research trip led by eXXpedition, a not-for-profit organization running all-women sailing voyages investigating ocean... Read more
This article is translated from press release in Japanese for your convenience. Forward-Looking Statements Statements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management... Read more